Novus therapeutics, inc. (NVUS)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Dec'13
ASSETS
Current assets:
Cash

11,785

8,791

10,814

13,703

9,056

-

16,324

19,189

22,523

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

-

-

-

-

-

12,972

-

-

-

17,233

19,094

22,498

24,400

1,103

18,630

12,156

14,303

24,023

33,168

59,084

94,162

105,256

105,464

31,753

Restricted cash

-

-

-

-

-

-

0

0

0

70

-

13

-

14

-

-

-

-

-

-

-

-

-

-

Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,088

31,771

39,947

39,934

39,935

24,110

-

0

-

-

Prepaid expenses and other current assets

1,088

1,180

1,482

1,478

1,265

1,304

786

1,889

1,505

1,697

1,941

2,332

1,231

33

1,616

2,259

2,737

3,213

3,762

3,562

2,170

2,255

1,260

425

Total current assets

12,873

9,971

12,296

15,181

10,321

14,276

17,110

21,078

24,028

19,000

21,035

24,843

25,631

1,150

36,334

46,186

56,987

67,170

76,865

86,756

96,332

107,511

106,724

32,178

Property and equipment, net

3

5

7

10

12

14

17

20

22

25

47

49

80

31

117

401

453

489

427

339

73

33

38

29

Operating lease asset, net

272

316

360

403

446

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30

Restricted cash

-

-

-

-

-

-

-

-

-

-

70

70

120

-

270

270

270

270

270

270

200

200

200

50

Goodwill

-

-

1,867

1,867

1,867

1,867

1,867

1,867

1,867

1,867

1,867

1,867

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

572

639

688

755

805

869

934

-

-

-

-

15

-

15

-

-

-

45

45

45

45

-

21

-

Total assets

13,720

10,931

15,218

18,216

13,451

17,026

19,928

22,965

25,917

20,892

23,019

26,844

25,831

1,196

36,721

46,857

57,710

67,974

77,607

87,410

96,650

107,744

106,983

32,287

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

741

329

256

753

480

689

751

706

449

418

189

374

276

338

886

1,846

1,886

1,208

1,652

1,704

3,434

765

2,889

5

Current operating lease liability

184

180

177

173

170

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued severance

-

-

-

-

-

-

90

224

428

668

963

1,300

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

953

813

1,228

1,022

2,591

1,845

762

522

742

354

1,154

1,486

-

113

-

-

-

-

-

-

-

-

-

-

Convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

3,447

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

2,143

-

5,458

5,971

4,291

4,954

4,005

2,943

2,320

3,478

2,483

2,204

Total current liabilities

1,878

1,322

1,661

1,948

3,241

2,534

-

-

-

-

2,306

3,160

2,419

-

6,344

7,817

6,177

6,162

5,657

4,647

5,754

4,243

5,372

2,209

Non-current operating lease liability

97

144

191

236

281

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term liabilities

-

-

-

-

-

-

-

-

-

-

94

245

48

-

120

156

-

88

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

126

-

51

13

-

-

-

-

Total liabilities

1,975

1,466

1,852

2,184

3,522

2,534

1,603

1,452

1,619

1,440

2,400

3,405

2,467

3,898

6,464

7,973

6,303

6,250

5,708

4,660

5,754

4,243

5,372

2,209

Commitments and contingencies (Note 5)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Redeemable convertible preferred stock (Series A, B-1, B-2, C, D-1, D-2, D-3 and E), $0.001 par value; no shares and 155,586,141 shares authorized at December 31, 2014 and 2013, respectively; no shares and 155,586,141 shares issued and outstanding at December 31, 2014 and 2013, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

85,345

Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized at March 31, 2020 and December 31, 2019; 3,796 and 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

0

0

0

-

-

-

0

19

0

0

0

0

0

0

0

0

-

0

Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2020 and December 31, 2019; 16,069,562 and 12,967,338 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

16

13

13

13

9

9

9

9

9

7

7

7

23

-

23

23

23

23

23

22

22

22

22

-

Additional paid-in capital

77,488

67,034

66,791

66,564

56,372

56,054

55,313

55,005

54,601

46,951

46,008

45,858

196,604

11,378

195,891

195,245

194,253

193,194

192,289

191,298

-

189,830

-

-

Receipts on account of Preferred A stock

-

-

-

-

-

-

-

-

-

-

-

-

-

291

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

6

-5

-55

8

-2

-

-

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

190,485

-

181,732

7,788

Accumulated deficit

-65,759

-57,582

-53,438

-50,545

-46,452

-41,571

-36,997

-33,501

-30,312

-27,506

-25,396

-22,426

-173,263

-14,390

-165,660

-156,390

-142,864

-131,438

-120,421

-108,568

-99,611

-86,351

-80,143

-63,055

Total stockholders’ equity

11,745

9,465

13,366

16,032

9,929

14,492

18,325

21,513

24,298

19,452

20,619

23,439

23,364

-2,702

30,257

38,884

51,407

61,724

71,899

82,750

90,896

103,501

101,611

-55,267

Total liabilities and stockholders’ equity

13,720

10,931

15,218

18,216

13,451

17,026

19,928

22,965

25,917

20,892

23,019

26,844

25,831

1,196

36,721

46,857

57,710

67,974

77,607

87,410

96,650

107,744

106,983

32,287